Revance Therapeutics, Stock Debt To Equity
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
Revance Therapeutics, fundamentals help investors to digest information that contributes to Revance Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Revance Stock. The fundamental analysis module provides a way to measure Revance Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Revance Therapeutics, stock.
Revance |
Revance Therapeutics, Company Debt To Equity Analysis
Revance Therapeutics,'s Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Revance Therapeutics, Debt To Equity | 2.94 % |
Most of Revance Therapeutics,'s fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revance Therapeutics, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Revance Therapeutics, has a Debt To Equity of 2.936%. This is 94.52% lower than that of the Pharmaceuticals sector and 84.83% lower than that of the Health Care industry. The debt to equity for all United States stocks is 93.97% higher than that of the company.
Revance Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revance Therapeutics,'s direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revance Therapeutics, could also be used in its relative valuation, which is a method of valuing Revance Therapeutics, by comparing valuation metrics of similar companies.Revance Therapeutics, is currently under evaluation in debt to equity category among its peers.
Revance Fundamentals
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.54) % | |||
| Current Valuation | 680.39 M | |||
| Shares Outstanding | 104.39 M | |||
| Shares Owned By Insiders | 8.55 % | |||
| Shares Owned By Institutions | 87.45 % | |||
| Number Of Shares Shorted | 4.51 M | |||
| Price To Earning | (7.60) X | |||
| Price To Book | 12.30 X | |||
| Price To Sales | 1.48 X | |||
| Revenue | 234.04 M | |||
| Gross Profit | 103.69 M | |||
| EBITDA | (290.64 M) | |||
| Net Income | (323.99 M) | |||
| Cash And Equivalents | 233.82 M | |||
| Cash Per Share | 3.20 X | |||
| Total Debt | 478.43 M | |||
| Debt To Equity | 2.94 % | |||
| Current Ratio | 3.38 X | |||
| Book Value Per Share | (1.55) X | |||
| Cash Flow From Operations | (216.57 M) | |||
| Short Ratio | 1.70 X | |||
| Earnings Per Share | (3.34) X | |||
| Price To Earnings To Growth | (0.64) X | |||
| Target Price | 9.47 | |||
| Number Of Employees | 597 | |||
| Beta | 0.95 | |||
| Market Capitalization | 381.02 M | |||
| Total Asset | 478.45 M | |||
| Retained Earnings | (2.08 B) | |||
| Working Capital | 249.64 M | |||
| Current Asset | 208.68 M | |||
| Current Liabilities | 17.52 M | |||
| Net Asset | 478.45 M |
About Revance Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revance Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revance Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revance Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |